|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 270.50 TWD | -2.70% |
|
-1.28% | -0.55% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Enjoy this offer
* See conditions on site
| Capitalization | 73.55B 2.29B 3.1B | P/E ratio 2024 * |
14.9x | P/E ratio 2025 * | 11.5x |
|---|---|---|---|---|---|
| Enterprise value | 80.19B 2.5B 3.38B | EV / Sales 2024 * |
4.31x | EV / Sales 2025 * | 3.55x |
| Free-Float |
58.07% | Yield 2024 * |
1.94% | Yield 2025 * | 2.73% |
More valuation ratios
* Estimated data
More news
Last Transcript: Lotus Pharmaceutical Co., Ltd.
More press releases
More news
| 1 day | -2.70% | ||
| 1 week | -1.28% | ||
| Current month | -5.75% | ||
| 1 month | +1.31% | ||
| 3 months | -5.91% | ||
| 6 months | -1.10% | ||
| Current year | -0.55% |
1 week
264.00
288.00
1 month
264.00294.50
Current year
210.50347.00
1 year
205.00347.00
3 years
81.90349.50
5 years
44.55349.50
10 years
40.50349.50
| Director | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 14-09-28 | |
I ling Tian
DFI | Director of Finance/CFO | - | 16-10-31 |
Ying Ming Yue
COO | Chief Operating Officer | - | 22-11-30 |
| Manager | Title | Age | Since |
|---|---|---|---|
Vilhelm Wessman
CHM | Chairman | 54 | 15-04-22 |
| Director/Board Member | 60 | 14-08-10 | |
| Director/Board Member | 60 | 15-04-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.01% | 99 M€ | +2.61% | - | |
| 0.00% | 7 M€ | +0.11% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -2.70% | -1.28% | +9.96% | +162.62% | 2.23B | ||
| +0.34% | -2.69% | +54.63% | +284.51% | 829B | ||
| +2.79% | +3.31% | +34.19% | +190.46% | 583B | ||
| -0.02% | -1.52% | +1.33% | -1.29% | 397B | ||
| -0.05% | -1.23% | +30.56% | +82.41% | 344B | ||
| +0.04% | -0.94% | +5.63% | +56.17% | 291B | ||
| -2.40% | -5.18% | +2.85% | -23.34% | 255B | ||
| -0.81% | -2.90% | +13.96% | +50.36% | 248B | ||
| +1.18% | -0.41% | +9.85% | +25.32% | 232B | ||
| +0.57% | -0.20% | +26.08% | +54.38% | 177B | ||
| Average | -0.05% | -1.94% | +18.90% | +88.16% | 335.85B | |
| Weighted average by Cap. | +0.49% | -2.27% | +26.50% | +123.11% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 18.49B 575M 780M | 21.36B 665M 901M |
| Net income | 4.77B 148M 201M | 6.16B 192M 260M |
| Net Debt | 6.16B 192M 260M | 2.32B 72.15M 97.85M |
More financial data
* Estimated data
Employees
1,099
Sector
Pharmaceuticals
Calendar
2024-11-06
- Q3 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-09-11 | 270.50 NT$ | -2.70% | 2,223,897 |
| 24-09-10 | 278.00 NT$ | -2.28% | 2,521,309 |
| 24-09-09 | 284.50 NT$ | +3.27% | 2,344,385 |
| 24-09-06 | 275.50 NT$ | +3.38% | 2,269,719 |
| 24-09-05 | 266.50 NT$ | -2.74% | 1,847,395 |
End-of-day quote Taiwan S.E., September 10, 2024
More quotes
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
270.50TWD
Average target price
394.80TWD
Spread / Average Target
+45.95%
- Stock Market
- Equities
- 1795 Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition